Journal: PLOS ONE

Article Title: Antimicrobial proteins from oyster hemolymph improve the efficacy of conventional antibiotics

doi: 10.1371/journal.pone.0312305

Figure Lengend Snippet: Effective antibacterial concentrations (μg/mL) of HPE and conventional antibiotics against a range of pathogens presented as MBC: Minimum bactericidal concentration (± standard deviations) and EC 50 : Median effective concentration (with 95% highest posterior density intervals [HPDI]). Effective concentrations are for antibiotics in the presence of HPE at sub-MIC concentrations (1–3 μg/mL) for susceptible species ( Streptococcus ) and at higher concentrations (6–12 μg/mL) for non/less-susceptible species ( S . aureus , and Gram-negative sp.) NT: not tested, NC: not calculable.

Article Snippet: S . pneumoniae (ATCC 51916) , Ampicillin , 8.03 (±2.2), 3.65 (0.35, 4.65) , 0.25 (±0.0), 0.13 (0.09, 0.17) , 0.125 (±0.0), 0.08 (0.06, 0.11) , 0.06 (±0.0), 0.02 (0.00, 0.06).

Techniques: Concentration Assay

Journal: PLOS ONE

Article Title: Antimicrobial proteins from oyster hemolymph improve the efficacy of conventional antibiotics

doi: 10.1371/journal.pone.0312305

Figure Lengend Snippet: Antibacterial (inhibition of planktonic growth) and antibiofilm (inhibition of biofilm formation) activity of SRO hemolymph fraction HPE alone, conventional antibiotics (ampicillin) alone, and HPE-antibiotic combination treatments where HPE was combined at fixed concentrations (1 or 3 μg/mL) with ampicillin at variable concentrations (1.0–0.002 μg/mL) tested against laboratory (ATCC 51916) (A) and clinical (14, 6B, 19F) strains (B-D) of S . pneumoniae .

Article Snippet: S . pneumoniae (ATCC 51916) , Ampicillin , 8.03 (±2.2), 3.65 (0.35, 4.65) , 0.25 (±0.0), 0.13 (0.09, 0.17) , 0.125 (±0.0), 0.08 (0.06, 0.11) , 0.06 (±0.0), 0.02 (0.00, 0.06).

Techniques: Inhibition, Activity Assay

Journal: PLOS ONE

Article Title: Antimicrobial proteins from oyster hemolymph improve the efficacy of conventional antibiotics

doi: 10.1371/journal.pone.0312305

Figure Lengend Snippet: catarrhalis (A) and laboratory strains of K . pneumoniae (B) and Nt Hi (C).

Article Snippet: S . pneumoniae (ATCC 51916) , Ampicillin , 8.03 (±2.2), 3.65 (0.35, 4.65) , 0.25 (±0.0), 0.13 (0.09, 0.17) , 0.125 (±0.0), 0.08 (0.06, 0.11) , 0.06 (±0.0), 0.02 (0.00, 0.06).

Techniques: Hi-C

Journal: PLOS ONE

Article Title: Antimicrobial proteins from oyster hemolymph improve the efficacy of conventional antibiotics

doi: 10.1371/journal.pone.0312305

Figure Lengend Snippet: Reduction in antibacterial and antibiofilm activity of SRO hemolymph fraction HPE following different heat treatments (storage at -80°C, storage at ambient laboratory temperature for 24 h [AT], heated to 37°C for 1 h or heated to 60°C for 1 h) tested against Streptococcus pneumoniae (ATCC 51916) at concentrations between 154.15–0.30 μg/mL.

Article Snippet: S . pneumoniae (ATCC 51916) , Ampicillin , 8.03 (±2.2), 3.65 (0.35, 4.65) , 0.25 (±0.0), 0.13 (0.09, 0.17) , 0.125 (±0.0), 0.08 (0.06, 0.11) , 0.06 (±0.0), 0.02 (0.00, 0.06).

Techniques: Activity Assay

Journal: RSC Medicinal Chemistry

Article Title: Potent trifluoromethoxy, trifluoromethylsulfonyl, trifluoromethylthio and pentafluorosulfanyl containing (1,3,4-oxadiazol-2-yl)benzamides against drug-resistant Gram-positive bacteria † †Electronic supplementary information (ESI) available: Synthesis and characterization data of compounds ( 1 H, 13 C NMR and HRMS). Bacterial strains, media, cell lines and reagents used. Protocols for the determination of the MICs and MBCs against bacteria, synergy of compounds with standard antibiotics, in vitro cytotoxicity analysis of compounds 6 , 11 , 12 and 13 against human colorectal and murine macrophage cells, hemolysis assay, time-kill kinetics analysis, intracellular infection of J774 cells with MRSA and treatment with compounds 6 and 12 . Table of bacterial isolates used in this study. See DOI: 10.1039/c9md00391f

doi: 10.1039/c9md00391f

Figure Lengend Snippet: The minimum inhibitory concentrations (MICs in μg mL –1 ) of compounds 6 , 11 , 12 and 13 against a panel of clinically important Gram-positive bacterial pathogens including Staphylococcus epidermidis , Streptococcus pneumoniae, Enterococcus faecalis , Enterococcus faecium and Listeria monocytogenes

Article Snippet: 24 table ft1 table-wrap mode="anchored" t5 caption a7 Bacterial strains a Compounds/control antibiotics 6 11 12 13 Vancomycin Linezolid Methicillin-sensitive Staphylococcus aureus ATCC 6538 8 1 0.5 0.5 1 0.5 Methicillin-sensitive Staphylococcus aureus NRS 107 4 1 0.25 0.125 1 0.5 MRSA NRS 119 8 1 0.5 0.06 1 >64 MRSA NRS382 (USA100) 8 1 0.5 0.5 2 1 MRSA NRS383 (USA200) 8 2 0.25 1 1 1 MRSA NRS384 (USA300) 4 0.5 0.5 0.5 1 1 MRSA NRS123 (USA400) 4 1 0.5 0.25 1 1 MRSA NRS 385 (USA500) 8 2 2 0.5 2 1 MRSA NRS 386 (USA700) 4 1 0.5 0.125 1 1 MRSA NRS 387 (USA800) 4 2 0.125 0.25 2 1 MRSA NRS 483 (USA1000) 4 1 0.5 0.25 2 1 MRSA NRS 484 (USA1100) 4 0.5 0.5 0.5 2 2 VRSA 10 4 1 0.5 0.25 >64 1 VRSA 12 8 1 0.5 0.125 >64 1 Open in a separate window a See ESI for sources of bacterial strains. caption a8 The minimum inhibitory concentrations (MICs in μg mL –1 ) of compounds 6 , 11 , 12 and 13 against methicillin-sensitive Staphylococcus aureus , methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Staphylococcus aureus (VRSA) strains table ft1 table-wrap mode="anchored" t5 caption a7 Bacterial strains a Compounds/control antibiotics 6 11 12 13 Vancomycin Linezolid Staphylococcus epidermidis NRS101 4 0.5 0.25 0.06 2 1 Cephalosporin- resistant Streptococcus pneumoniae ATCC 51916 2 2 0.25 0.25 0.5 1 Methicillin- resistant Streptococcus pneumoniae ATCC 700677 1 1 0.25 0.125 1 1 Enterococcus faecalis ATCC 51299 (VRE) 4 8 4 2 32 1 Enterococcus faecium ATCC 700221 (VRE) 4 4 4 2 >64 1 Listeria monocytogenes ATCC 19111 2 2 0.5 0.125 0.5 0.5 Open in a separate window a See ESI for sources of bacterial strains. caption a8 The minimum inhibitory concentrations (MICs in μg mL –1 ) of compounds 6 , 11 , 12 and 13 against a panel of clinically important Gram-positive bacterial pathogens including Staphylococcus epidermidis , Streptococcus pneumoniae, Enterococcus faecalis , Enterococcus faecium and Listeria monocytogenes

Techniques:

Journal: Applied and Environmental Microbiology

Article Title: Predatory Organisms with Untapped Biosynthetic Potential: Descriptions of Novel Corallococcus Species C. aberystwythensis sp. nov., C. carmarthensis sp. nov., C. exercitus sp. nov., C. interemptor sp. nov., C. llansteffanensis sp. nov., C. praedator sp. nov., C. sicarius sp. nov., and C. terminator sp. nov.

doi: 10.1128/AEM.01931-19

Figure Lengend Snippet: ANI and dDDH values for pairwise comparisons between the eight candidate strains, C. exiguus DSM 14696 T , and C. coralloides DSM 2259 T

Article Snippet: The type strains of C. coralloides (DSM 2259 T ) and C. exiguus (DSM 14696 T ) were obtained from the DSMZ (German Collection of Microorganisms and Cell Cultures).

Techniques: